Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
16.18 USD | +0.09% | +9.06% | -23.97% |
Financials (USD)
Sales 2024 * | 65.76M | Sales 2025 * | 121M | Capitalization | 2.3B |
---|---|---|---|---|---|
Net income 2024 * | -410M | Net income 2025 * | -442M | EV / Sales 2024 * | 13.6 x |
Net cash position 2024 * | 1.41B | Net cash position 2025 * | 1.17B | EV / Sales 2025 * | 9.34 x |
P/E ratio 2024 * |
-6.2
x | P/E ratio 2025 * |
-6.12
x | Employees | 445 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 86.18% |
Latest transcript on Denali Therapeutics Inc.
1 day | +4.66% | ||
1 week | +3.86% | ||
Current month | +4.66% | ||
1 month | -21.40% | ||
3 months | -1.40% | ||
6 months | -15.08% | ||
Current year | -24.70% |
Managers | Title | Age | Since |
---|---|---|---|
Alexander Schuth
FOU | Founder | 50 | 13-10-13 |
Ryan Watts
FOU | Founder | 48 | 13-10-13 |
Joe Lewcock
CTO | Chief Tech/Sci/R&D Officer | - | 19-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Vicki Sato
CHM | Chairman | 75 | 15-03-31 |
Jay Flatley
BRD | Director/Board Member | 71 | 15-03-31 |
David Schenkein
BRD | Director/Board Member | 66 | 15-03-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.31% | 0 M€ | 0.00% | - | |
0.31% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-02 | 16.32 | +0.96% | 15 741 |
24-05-01 | 16.16 | +4.66% | 1,361,291 |
24-04-30 | 15.44 | -1.03% | 969,506 |
24-04-29 | 15.6 | +1.10% | 910,476 |
24-04-26 | 15.43 | +3.14% | 1,122,313 |
Delayed Quote Nasdaq, May 01, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-24.70% | 2.3B | |
-1.17% | 104B | |
+2.87% | 97.47B | |
+4.98% | 22.25B | |
-14.77% | 21.68B | |
-8.89% | 18.2B | |
-39.98% | 17.02B | |
-13.21% | 16.36B | |
+8.55% | 14.39B | |
+35.75% | 12.37B |
- Stock Market
- Equities
- DNLI Stock